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  25 
ABSTRACT 26 
Most genomic alterations are tolerated while only a minor fraction disrupts molecular 27 
function sufficiently to drive disease. Protein kinases play a central biological 28 
function and the functional consequences of their variants are abundantly 29 
characterized. However, this heterogeneous information is often scattered across 30 
different sources, which makes the integrative analysis complex and laborious. 31 
wKinMut-2 constitutes a solution to facilitate the interpretation of the consequences 32 
of human protein kinase variation. Nine methods predict their pathogenicity, 33 
including a kinase-specific random forest approach. To understand the biological 34 
mechanisms causative of human diseases and cancer, information from pertinent 35 
reference knowledgebases and the literature is automatically mined, digested and 36 
homogenized. Variants are visualized in their structural contexts and residues 37 
affecting catalytic and drug-binding are identified. Known protein-protein interactions 38 
are reported. Altogether, this information is intended to assist the generation of new 39 
working hypothesis to be corroborated with ulterior experimental work. The 40 
wKinMut-2 system, along with a user manual and examples is freely accessible at 41 
http://kinmut2.bioinfo.cnio.es, the code for local installations at 42 
https://github.com/Rbbt-Workflows/KinMut2. 43 
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  49 
INTRODUCTION  50 
Only a minor fraction of the large number of variants discovered with current high-51 
throughput next generation sequencing (NGS) methodologies (Sjöblom et al. 2006; 52 
Greenman et al. 2007; Wood et al. 2007) are causally implicated in disease. 53 
Discerning between disease-causing and neutral variants remains a challenge that 54 
requires computational methods to guide and prioritize the experiments (Baudot et al. 55 
2009). The protein kinase superfamily plays a central role in the cell and its members 56 
have been studied in detail. Consequently, this superfamily constitutes a key example 57 
where abundant experimental evidence linking variants and disease, including some 58 
types of cancer, exists (Krallinger et al. 2009; Stratton et al. 2009). Albeit abundant 59 
respect to other protein families, this information is often heterogeneous, disperse and 60 
incomplete, which complicates the analysis of the consequences of variants.  61 
wKinMut-2 represents an evolution on the original system that improves content 62 
and functionalities. Following our previous work (Izarzugaza et al. 2012; Izarzugaza 63 
et al. 2013), wKinMut-2 collects, integrates and digests relevant information extracted 64 
from diverse sources, including the one directly extracted from the literature. 65 
Residues are evaluated with respect to their catalytic role, including binding of known 66 
drugs broadly used in the clinic, and the involvement in interaction interfaces. 67 
Variants are characterized at the protein, domain and residue levels and represented 68 
within the context of 3D structures of the proteins. Furthermore, wKinMut-2 69 
integrates information on predicted consequences of variants from 9 complementary 70 
methods, including a new random forest-based method trained with kinase specific 71 
information.  72 
Previous attempts to the interpretation of variants affecting the human kinome exist 73 
(Supp. Table S1), although they often incorporate a limited number of information 74 
sources and differ in rationale. For example, MoKCa (Richardson et al. 2009) 75 
constitutes a valuable resource that integrates information for known kinase variants. 76 
Annotations span different levels, consider the structural context of variants and 77 
include examples of expert curated assessment of the functional consequences. 78 
Unfortunately, annotations cannot be inferred on-the-fly for newly discovered genetic 79 
events; this static character hinders the applicability of MoKCa in a clinical setting. 80 
Examples of dynamic prediction servers also exist. Torkamani (Torkamani and 81 
Schork 2007) proposed a machine-learning methodology to predict the impact of 82 
kinase variants in cancer onset. Moreover, ProKinO (McSkimming et al. 2015) 83 
follows a new approach that results in the generation of testable hypotheses through 84 
an iterative process. This includes aggregate ontology querying and conceptualization 85 
of diverse forms of information (e.g., conserved sequence, structural motifs) in a 86 
machine-readable, human-understandable form. Both methodologies might identify 87 
causative variants but lack the contextualization of the findings with existing 88 
knowledge. Contrarily to these approaches, wKinMut-2 constitutes a one-stop shop to 89 
ease the interpretation of the consequences of variants in human protein kinases 90 
through the combination of imputed and validated information: Predictions of the 91 
functional consequences of kinase variants are integrated with information from 92 
knowledge bases, literature mining, and 3D analysis of protein structures. 93 
  94 
METHODS 95 
Web server framework 96 
wKinMut-2 has been implemented primarily in Ruby as a workflow accessible 97 
through a REST interface. Consequently, results can be rendered in multiple formats 98 
including TSV (tab-separated values), JSON and HTML. Here we focus mainly on 99 
the latter, although fully programmatic access to the predictions is documented in the 100 
web site. External resources of information, such as gene descriptions or iHOP 101 
interactions, are queried remotely through the Internet on demand; subsequent 102 
accesses benefit from a cache system. Overall back-end performance is improved by a 103 
caching scheme that allows persisting job results and faster web interface 104 
visualization. wKinMut-2 is publicly available, including documentation and help 105 
pages, at http://kinmut2.bioinfo.cnio.es. The source code has been deposited in 106 
GitHub (https://github.com/Rbbt-Workflows/KinMut2) under a GPL version 3 107 
licence. 108 
Submission of variant for analysis 109 
Figure 1 displays a typical workflow in the analysis of protein kinase variation with 110 
wKinMut-2. Single point missense events affecting the human kinome are the input to 111 
the server. Variants are defined by a UniProt accession, a position in the protein and 112 
the wild-type and alternative amino acids. Consequently, a change from Valine to 113 
Glutamate in position 600 of the B-Raf proto-oncogene would be encoded as P15056 114 
V600E (Supp. Fig. S1, panel a). Non-standard amino acids (B and Z) will be 115 
decomposed into separate instances of their standard counterparts (D, N and E, Q, 116 
respectively) whereas synonymous and truncating variants will be excluded from the 117 
analysis. Additionally, we exclude input instances where the introduced wild-type 118 
amino acid does not coincide with the expected equivalent position in the canonical 119 
protein sequence. This identifies input errors and avoids incorrect annotations in the 120 
downstream analysis. 121 
 122 
Datasets and data pre-processing  123 
In the present work we used publicly available datasets: (1) UniProt Variant Pages 124 
(Yip et al. 2008), (2) KinMutBase (Ortutay et al. 2005), (3) Kin-Driver (Simonetti et 125 
al. 2014), (4) COSMIC (Bamford et al. 2004), and (5) ClinVar (Landrum et al. 2014) . 126 
We decided to use all variants for which a classification as neutral/disease was 127 
available in UniProt Variant Pages. No filtering based on the disease that might have 128 
originated the classification was exerted. A total of 850 variants affecting 299 kinases 129 
were not used in the analysis because they were listed as unclassified in UniProt. 130 
After this pre-processing step, 1021 unique variants in 84 proteins kinases constitute 131 
the disease class whereas the neutral class consists of 2668 variants in 450 proteins. A 132 
link to the full list of selected variants is available in the website (see help pages). 133 
Other additional details and the distribution of variants respect to the classification 134 
features (i.e., membership to kinase groups, gene ontology terms, PFAM domains, 135 
amino acid and their biochemical properties, residue conservation, and functional 136 
annotations in UniProt, FireDB and Phospho.ELM) are displayed along with the 137 
description of each individual feature in Supp. Fig. S4 - S13. 138 
 139 
Data availability and reproducibility of results 140 
The datasets utilised for training and evaluation of KinMutRF, included the data 141 
splits in the 10-fold cross-validation, are available through the help pages of our web 142 
server. The selected 3689 variants described in the previous section were randomly 143 
divided into 10 bins of similar sizes, constrained only by the rule that different 144 
variants affecting the same protein should be forced into the same bin. We 145 
incorporated this rule to avoid overestimating the performance of the classification 146 
due to similarities between elements of the training and evaluation sets. 147 
For each dataset, we compiled tab-separated files containing the classification 148 
features. To assess the contribution of individual features we calculated their 149 
information gain with respect to the classification classes using the 150 
InfoGainAttributeEval function in Weka. More details about identification of the most 151 
relevant features for prediction (see Supp. Table S2), and evaluation of KinMutRF’s 152 
performance according to external datasets are provided in Supplementary Materials.  153 
RESULTS 154 
Interpretation of the consequences of variants 155 
By default, wKinMut-2 presents a ‘Summary table’ that provides a quick overview 156 
of the results and helps to prioritize variants of interest for detailed analysis. The 157 
summary highlights the trait/disease annotations, and molecular details about the 158 
investigated variants. For example: i) relationships among human variations and 159 
phenotypes with supporting evidences annotated in ClinVar (Landrum et al. 2014); ii) 160 
number of COSMIC samples with variants overlapping that same residue; iii) variants 161 
overlapping a post-translational modified residue, a ligand-binding or catalytic 162 
residue, and residues experimentally altered by mutagenesis; iv) number of other 163 
damage predictors that predict the variant as damaging; and v) the groups to which 164 
the kinases belong according to the classification in KinBase (Manning et al. 2002a; 165 
Manning et al. 2002b; Miranda-Saavedra and Barton 2007), and the color coded 166 
pathogenicity scores according to our kinase-specific random forest-based predictor. 167 
Further details will be provided in the corresponding section. Note that a summary 168 
report of the prediction and all relevant files for the prediction are available for direct 169 
download from this page. 170 
The primary goal of wKinMut-2 is to aid computational biologists and clinicians to 171 
understand and to interpret the consequences of disease-causing variants acquired by 172 
human protein kinases. Expanded information is gathered and provided when the user 173 
clicks on the ‘View details’ button (Supp. Fig. S1, panel b). This spawns a multi-174 
tabular page including the characterization of the variants at the protein, domain and 175 
residue level; the representation of the variants onto known protein structures and 176 
models including the analysis of the disruption of the protein-protein interaction 177 
interfaces; the prediction of pathogenicity using different methodologies; the 178 
collection of mentions of the variants in dedicated knowledgebases, complemented 179 
with information mined from the literature and the study of the known and predicted 180 
interaction partners. Each of these tabs will be detailed in the following sections and 181 
their main characteristics explained.  182 
General description of the mutated kinases 183 
The first view presents a ‘General’ tab (Supp. Fig. S1, panel c). This section 184 
compiles diverse information about the kinase that harbors a variant of interest. This 185 
includes the gene name and the description from UniProt, the protein identifier in 186 
Ensembl and the classification in kinase groups as defined by KinBase (Manning et 187 
al. 2002a; Manning et al. 2002b; Miranda-Saavedra and Barton 2007). In addition, as 188 
a proxy to understand the cellular role of the protein, we list GeneOntology 189 
(Ashburner et al. 2000) annotations grouped by subontology (i.e., Molecular 190 
Function, Cellular Compartment and Biological Process). Besides we include three 191 
main types of information about: i) essential or non-essential phenotype-changing of 192 
the homologous gene in mouse based on the information collected by dbNSFP (Liu et 193 
al. 2013) from the Mouse Genome Informatics database (Georgi et al. 2013); ii) US 194 
FDA (Jänne et al. 2009) approved protein kinase inhibitors 195 
(http://www.brimr.org/PKI/PKIs.htm) and iii) bioactive compounds and screening 196 
data for kinases, extracted from Kinase SARfari an integrated chemogenomics 197 
workbench available at EMBL-EBI 198 
(https://www.ebi.ac.uk/chembl/sarfari/kinasesarfari). 199 
Mapping variants onto protein structures 200 
The effect of variants is better understood in their own structural contexts under the 201 
assumption that pathogenic variants distort protein function and structural stability 202 
(Izarzugaza et al. 2009b; Izarzugaza et al. 2011). Mapping variants from sequences to 203 
3D structures is not trivial (Izarzugaza et al. 2009a). To bridge this gap, wKinMut-2 204 
enables the visualization of variants onto the available structures and models (Supp. 205 
Fig. S1, panel d) in PDB and Interactome3D. We chose Jmol provided the versatility 206 
of the built-in console, which permits customized representations. In addition, 207 
information contextualizing the variant regarding to the affected protein domains is 208 
retrieved from Ensembl. 209 
Predicting the pathogenic potential of variants 210 
wKinMut-2 provides the likelihood of a given variant to be causally implicated in 211 
disease in the ‘Pathogenicity’ section (Supp. Fig. S1, panel f). We provide predictions 212 
from nine different methodologies ranging from the most classical evolutionary 213 
perspective provided by SIFT, to a new random forest machine learning classifier 214 
adapted for the prediction of pathogenesis within the human kinome. Predictions are 215 
directly extracted from dbNSFP v2.8 (https://sites.google.com/site/jpopgen/dbNSFP) 216 
(Liu et al. 2013) and include likelihood scores from SIFT release August 2011 217 
(http://sift.jcvi.org/) (Ng and Henikoff 2003), Polyphen2 v2.2.2 218 
(http://genetics.bwh.harvard.edu/pph2/)  (Adzhubei et al. 2010), LRT release 219 
November 2009 (http://www.genetics.wustl.edu/jflab/lrt_query.html) (Chun and Fay 220 
2009), MutationTaster release 2013 (http://www.mutationtaster.org/) (Schwarz et al. 221 
2010) , MutationAssessor release 2 (http://mutationassessor.org/) (Reva et al. 2011), 222 
FATHMM v2.3 (http://fathmm.biocompute.org.uk) (Shihab et al. 2013), VEST3 v3.0 223 
(http://karchinlab.org/apps/appVest.html)  (Carter et al. 2009) and CADD v1.0 224 
(http://cadd.gs.washington.edu/) (Grimm et al. 2015). In addition to these, wKinMut-2 225 
implements a new method specific to the protein kinase superfamily named 226 
KinMutRF. This method relies on a random forest classifier consisting of 26 decision 227 
trees that evaluate a number of sequence-derived features that characterize variants 228 
affecting human protein kinases at different levels: a) at the gene level, including 229 
membership to a Kinbase group and Gene Ontology categories; b) at the domain 230 
level, using PFAM domains; and c) at the residue level, involved amino acids types, 231 
changes in biochemical properties, functional annotations from UniProt (Yip et al. 232 
2008), Phospho.ELM (Dinkel et al. 2011) and FireDB (Lopez et al. 2007). These are 233 
described in detail in the corresponding section of the Supplementary Materials. The 234 
focus on the protein kinase superfamily enabled the choice of features unique to this 235 
superfamily. These kinase-specific annotations greatly increase the accuracy of the 236 
classification of variants. Each prediction is accompanied with a reliability score and 237 
the annotations giving rise to the predictions to facilitate the biological interpretation 238 
of the results. To provide an example of the functionality of wKinMut-2, we applied 239 
the method to a reduced dataset of BTK variants. Table 1 shows an output of the 240 
wKinMut-2 annotations in comparison with the PON-BTK   method. The evaluation 241 
of the prediction performance of the 9 methods in different kinase datasets following 242 
the best practices in the field (Vihinen 2012; Grimm et al. 2015) is given in Supp. 243 
Table S3.  244 
In the following sections we will discuss how the combination of prediction of 245 
pathogenicity and integration of information can enhance our understanding of the 246 
consequences of variants and facilitate the generation of working hypotheses.  247 
 248 
Variation in protein interaction interfaces and in the vicinity of the known 249 
functional sites 250 
Structure-PPi (http://structureppi.bioinfo.cnio.es/Structure) (Vazquez et al. 2015) is a 251 
system to facilitate the analysis of variants in the context of protein complexes. The 252 
system combines information from protein structures with functional annotations 253 
from a number of relevant databases and reports protein features (e.g., functional 254 
domains, known somatic variation in different types of cancer, UniProt annotations 255 
from missense variants, ligand binding residues, catalytic sites) that overlap the 256 
variant’s ‘direct matches’ or their ‘neighbors’ in close physical proximity (Supp. Fig. 257 
S1, panel e) defined as 5 angstroms spatial distance or adjacent in the sequence if no 258 
PDB covers that area. When variants affect the interfaces of protein complexes (when 259 
the variant is at a distance of less than 8 angstroms from a residue in the partner 260 
protein), Structure-PPi also reports the partner proteins, and the residues in those 261 
proteins that are in close proximity to the variant. 262 
In order to illustrate the power of the integration of information in the analysis of the 263 
consequences of variation, we used Structure-PPi to analyze the variants that 264 
KinMutRF failed to predict as pathogenic in the Kin-Driver (Simonetti et al. 2014) 265 
collections, as described in the Supplementary Material. Structure-PPi identified 266 
(features score>3) 64.89% (61/94) and 61.54% (8/13), respectively, of the activating 267 
and deactivating variants erroneously predicted by the pathogenicity classifier. 268 
Complementary annotations from Structure-PPi provide information about the 269 
functional role of the affected residues. For example, considering a deactivating 270 
variant in the STK11 serine/threonine-protein kinase p.D176N, Structure-PPi reveals 271 
that Asp-176 is a catalytic residue (Firestar and UniProt features) that accommodates 272 
several variants in lung cancer. This is also true for his structural neighbors, which 273 
present variants in different cancer types including lung, colon, cervix, kidney and 274 
leukemia. Two of these structural neighbors Lys-178 and Asn-181 are located in the 275 
ATP binding pocket; being in close structural proximity, Asp-176 might be relevant 276 
for the correct positioning of them.  277 
Variation in scientific knowledgebases 278 
A plethora of scientific databases approaches the consequences of variants from a 279 
variety of complementary perspectives. wKinMut-2 (Supp. Fig. S1, panel g) 280 
aggregates information from the UniProt Variant Pages (Yip et al. 2008), 281 
KinMutBase (Ortutay et al. 2005), Kin-Driver (Simonetti et al. 2014), COSMIC 282 
(Bamford et al. 2004)  and ClinVar (Landrum et al. 2014) and provides digested 283 
contextual information about the variants. Of particular interest, experimental 284 
evidence relating variants and disease, being cancer a recurrent example. Users of 285 
previous versions of the tool would notice that SAAPdb is not included in the current 286 
implementation, as its authors have discontinued it.  287 
Mining of variants from the literature 288 
Mining the literature complements the information sourced from the databases. A 289 
substantial number of references describe the experimental conditions or the specific 290 
background of the patients. Furthermore, in some cases the mined articles may 291 
describe the biochemical mechanisms by which variants might lead to the 292 
corresponding diseases. As these aspects are essential for the correct interpretation of 293 
the consequences of variation, wKinMut-2 collects mentions to kinase variants from 294 
the literature using SNP2L (Krallinger et al. 2009). Our literature-mining pipeline 295 
extracts and disambiguates automatically references to variants in both PubMed 296 
abstracts and full text articles. Strict internal filters increase the reliability of SNP2L; 297 
after variation mentions and kinases have been identified in a text, SNP2L checks the 298 
coherence of the mined amino acids and the expected sequences to reduce the number 299 
of spurious hits. SNP2L results are displayed under the ‘Literature’ tab of wKinMut-2 300 
(Supp. Fig. S1, panel h).  301 
Identification of interaction partners 302 
Two methods are used for the exploration of protein-protein interactions. First, the 303 
‘iHop’ tab (Supp. Fig. S1, panel i) elucidates known and inferred protein-protein 304 
interaction partners. iHop (Hoffmann and Valencia 2005)  has proven a useful text 305 
mining system to automatically mine interaction partners in PubMed abstracts. In 306 
order to provide the interactions in their context, results displayed include specific 307 
sentences from the literature as well as pointers to the original articles. Secondly, the 308 
‘String’ tab (Supp. Fig. S1, panel j) graphically shows the interactions described for 309 
the human kinome in the homonymous database (Szklarczyk et al. 2015). Evidence 310 
for interactions include gene neighborhood and gene fusion events, co-occurrence of 311 
the proteins across species, co-expression of genes in the same or other related 312 
species, experiments stored in databases as well as text-mining of PubMed abstracts. 313 
USE CASES 314 
To illustrate the utility of wKinMut-2, we describe next two examples where the 315 
system is used to draw hypotheses about the role of kinase variants in the onset of 316 
human diseases.  317 
The p.V600E variant in the B-Raf proto-oncogene. 318 
The B-Raf proto-oncogene is involved in the transduction of the mitogenic signals 319 
from the cell to the membrane of the nucleus. As described in the ‘General’ tab of 320 
wKinMut, this kinase regulates the MAPK/ERKs signal transduction pathway by 321 
phosphorylation of MAP2K1. The variant in position 600 from Valine to Glutamate 322 
used to illustrate the example in Supp. Fig. S1 is recurrently found in the literature 323 
associated to certain types of cancer including colorectal cancer, sarcoma, melanoma, 324 
thyroid carcinoma and ovarian serous carcinoma. These observations are coherent 325 
with the information obtained from the ‘Literature’ and ‘Databases’ tabs of wKinMut-326 
2. Furthermore, the ‘Pathogenicity’ tab shows that there is a consensus among the 327 
predictors to classify this variant as pathogenic. According to Structure-PPi 328 
annotations, p.V600E could affect the ATP-binding because due to the proximity to 329 
Phe-468, localized in the ATP-binding region (PDB ID: 3tv4, chain B). Phe-468 has 330 
been reported as substituted (p.F468S, VAR_035097) in Cardiofaciocutaneous 331 
syndrome 1 as well as in colorectal cancer. In addition, a characterization of the 332 
functional and biochemical properties is provided. Although p.V600E is harbored in 333 
the protein kinase domain, the affected residue does not seem to play a direct 334 
functional role. By contrast, the p.V600E variant may confer the activated phenotype 335 
by destabilization of the structure of the protein as it induces substantial changes in 336 
biochemical properties like hydrophobicity, formal charge, volume and C-beta 337 
branching. In addition, several records in the literature from the ‘Literature’ and 338 
‘iHop’ tabs suggest that p.V600E might be associated with genomic instability 339 
leading to secondary genetic events that might account for its aggressive phenotype.  340 
 The p.P250R variant in the interface between the human fibroblast growth 341 
factor receptor 3 and its interaction partner FGF1. 342 
This example illustrates a case where the predictors do not provide a consensus 343 
classification. The p.P250R variant is considered pathogenic by KinMutRF, SIFT, 344 
Polyphen2 and FATHMM, whereas MutationTaster, MutationAssessor, VEST3 and 345 
CADD consider it neutral. These predictions are inconclusive. Interestingly, the 346 
variant appears in the ‘Databases’ tab associated with Muenke’s syndrome and the 347 
‘Literature’ tab reports plenty of pointers to publications discussing the role of this 348 
variant in some aberrant phenotypes including craniosynostosis, epidermal 349 
hyperplasia and Apert and Crouzon syndromes. Moreover, Proline-250 is adjacent to 350 
an activating variant, p.S249C, previously described in benign epidermal tumors 351 
(Logié et al. 2005).  352 
The correct assembly of two of more proteins in a complex is highly dependent on the 353 
physic-chemical properties of the interaction interfaces. For this reason, the amino 354 
acids conforming those functional surfaces are tightly preserved through evolution 355 
and modification of such residues commonly leads to aberrant phenotypes. According 356 
to the Structure-PPi, both p.P250R and p.S249C target the interaction interface 357 
between FGFR3 and FGF1 (Supp. Fig. S2). Following the diverse literature pointers 358 
provided, we hypothesize that the stimulation of downstream developmental 359 
pathways might cause the aberrant phenotype and we propose the disruption of the 360 
protein-protein interfaces as a plausible mechanism to be confirmed by further 361 
experimental work.  362 
DISCUSSION  363 
Protein kinases constitute a broad superfamily involved in relevant physiological 364 
functions. Although most variation affecting protein kinases is functionally neutral 365 
and tolerated by the cells, many examples have been published associating human 366 
protein kinase variants with disease, and particularly with cancer. With the advent of 367 
NGS technologies, the identification of variants is routine in most laboratories; 368 
however, the exploration of the consequences on the phenotypes of each individual 369 
event remains a considerable challenge. 370 
Here we describe a unified system, named wKinMut-2, that facilitates the 371 
identification and the interpretation of pathogenic variants in the human kinome.  372 
The system summarizes information about pathogenicity of variants annotated in 373 
the ClinVar database, number of tumor samples with variants over that same residue 374 
or close to that residue, number of sites that have been experimentally altered by 375 
mutagenesis, sites of post-translational modifications, ligand-binding sites, etc. 376 
wKinMut-2 offers direct prediction of the potential pathogenicity of non-377 
synonymous single amino acid variants with eight independent methods plus a new 378 
kinase-specific predictor. As most pathogenic variants disrupt the function and 379 
structural stability of the protein, a random forest-based approach evaluates changes 380 
in the properties of the affected amino acids. The system was trained with features 381 
that include the physicochemical properties of the amino acids, the sequence 382 
conservation according to SIFT and functional annotations from Phospho.ELM, 383 
FireDB and UniProt. These features apply generally to any protein. In addition, we 384 
consider kinase-specific properties such as membership to a specific group of kinases, 385 
prevalence of certain GO terms in disease associated kinases and the relevance of 386 
PFAM domains. One could argue the need for a new family-specific prediction 387 
method, in the wealth of methodologies available. We performed a cross-validation 388 
experiment that analyzed the prediction of 8 systems on the 3689 kinase variants in 389 
UniProt for which an annotation of pathogenicity is available. The benchmark (Supp. 390 
Table S3) shows that KinMutRF outperforms most classifiers, with the exception of 391 
VEST3 where closely similar performance is achieved. It is important to highlight at 392 
this point that the performance of predictors competing with KinMutRF might be 393 
optimistically interpreted due to the fact that a fraction of variants in the evaluation 394 
set used in this benchmark might had been presented to the classifier during its own 395 
training phase. Some authors refer to this relevant effect as type I circularity (Grimm 396 
et al. 2015). This effect has been considered in the development and evaluation of our 397 
methodology. In addition to attaining full comprehension of the datasets, a 398 
concomitant added value of an in-house system is the control over the frequency of 399 
re-training. Particularly, in the event of new kinase variants being discovered and 400 
classified. Moreover, VEST3 is intended for the identification of variation in exomes 401 
rather than for the investigation of individual events. Consequently, it is designed to 402 
partake in bioinformatics pipelines, often in memory-demanding computational 403 
scenarios and no web interface is provided. This might not be optimal in a clinical 404 
setting. Finally, our experience in the context of clinical cancer genomics suggests 405 
that the combination of different prediction methods takes advantage of the different 406 
prediction features and facilitates interpretation of the results in combination with 407 
other available sources, as in the FGF1 example presented above.  408 
A common approach to exploit our integrative approach presented here would be to 409 
start by using one or more of the scores from the pathogenicity predictors to prioritise 410 
the variants of interests, and then proceed to an in-depth analysis using the other 411 
integrated tools to devise a functional role and or a biochemical mechanism. Our 412 
analyses demonstrated with an independent manually curated dataset that current 413 
methods to predict the pathogenicity of variants are not sensitive enough to 414 
characterize variants alone and that activating variation constitutes a particularly 415 
challenging scenario. This highlights the need of integrative tools that combine 416 
prediction and information compilation. wKinMut-2 integrates digested information 417 
from a number of selected resources, which  helps to interpret the consequences of 418 
variants and can be used to draw hypothesis regarding the mechanisms linking 419 
variants to the alterations of the structure and function of the kinases, and indirectly 420 
point to the possible relation with observed phenotypes or diseases. The information 421 
provided, might constitute a basis for the design of new experimental work. 422 
Particularly relevant for the interpretation of the variants is the visualization of the 423 
information in the context of the corresponding protein structures, the mentions of the 424 
involvement of the variants in previous disease studies in publications or large-scale 425 
cancer genome projects. wKinMut-2 also includes information automatically 426 
extracted from the literature with our in-house tools; possible interaction partners are 427 
mined from PubMed abstracts with iHop and variant mentions are gathered from the 428 
literature using SNP2L, which provides a substantial addition to the information 429 
provided by public databases and repositories. Both tools display the particular 430 
sentences in the literature that support the association and supply external references 431 
to the original publications. 432 
We have described hereby a tool to study the links between kinase variation and 433 
disease. The examples provided highlight how raw predictions of pathogenicity are 434 
complemented by the integration and digestion of information from multiple sources 435 
and how this information can be used to propose further experimental work. 436 
Nevertheless, it is still necessary that resources of the like develop further, aiming to 437 
the automatic integration and processing of the wealth of information. The ultimate 438 
goal should be the reliable generation of hypotheses to explain the underlying 439 
biological mechanisms relating causative variants and diseases as a necessary step 440 
towards routine personalized treatment in the clinic.  441 
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FIGURE LEGENDS 569 
Fig. 1:  The different components of wKinMut-2 help to identify and interpret 570 
pathogenic variants in human protein kinases. 571 
 572 
TABLES 573 
Table 1: Annotation of BTK variants by wKinMut-2 and PON-BTK methods. 574 
 575 
Variants wKinMut-
2 
PON-P UniProt annotations
a
 
p.E41K disease n.a. No effect on phosphorylation of GTF2I 
p.P189A disease n.a. No effect on phosphorylation of GTF2I 
p.Y223F neutral n.a. Loss of phosphorylation of GTF2I 
p.W251L disease n.a. No effect on phosphorylation of GTF2I 
p.R307G disease n.a. Variant in XLA (VAR_006231); loss of activity 
p.R307K disease n.a. Loss of phosphorylation of GTF2I 
p.K430E disease Path. Variant in XLA (VAR_006242); loss of 
phosphorylation of GTF2I 
p.R520Q disease Path. Variant in XLA (VAR_006251); severe; prevents 
activation due to absence of contact between the 
catalytic loop and the regulatory phosphorylated 
residue 
p.R525Q disease Path. Variant in XLA (VAR_006255); severe; disturbs 
ATP-binding 
p.Y551F disease Path. Loss of phosphorylation of GTF2I 
p.R562P disease Path. Variant in XLA (VAR_006259). Corresponds to 
variant rs28935176:R562P 
p.E567K disease Path. Variant in XLA (VAR_006261); severe 
p.E589G disease Path. Variant in XLA (VAR_006265); moderate; 
interferes with substrate binding 
p.G594E disease Path. Variant in XLA (VAR_006268); interferes with 
substrate binding 
p.G613D disease Path. Variant in XLA (VAR_006272); interferes with 
substrate binding and/or domain interactions 
p.Y617E disease n.a. Defective in mediating calcium response 
a
Identification codes in parenthesis corresponds to entries in the file humsavar.txt 576 
(release 2015_06 of 27-May-2015) from the Swiss-Prot Variant Pages available at 577 
http://www.uniprot.org/docs/humsavar. XLA: X-linked agammaglobulinemia. 578 
Annotations according to wKinMut-2. PON-P: prediction of pathogenicity by the 579 
PON-BTK method (Izarzugaza et al. 2009b; Izarzugaza et al. 2011; Väliaho et al. 580 
2015). Predictions of pathogenic (Path.) or non-pathogenic (Non-Path) variants are 581 
available at http://structure.bmc.lu.se/PON-BTK/. n.a.: no annotation. 582 
 583 
